Indolent B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating reduced-dose radiotherapy for indolent B-cell non-Hodgkin lymphoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma [Phase 1, Phase 2]
Genmab-sponsored first-in-human trial in relapsed/refractory B-cell lymphomas spans Phase 1/2 and is currently active/not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 study evaluating ALX148 in combination with Rituximab and Lenalidomide for various B-cell non-Hodgkin lymphomas, with the trial …
-
CLINICAL_TRIALS trial_result · 2025-11-05Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) [Phase 2]
This is a Phase 2 clinical trial evaluating JCAR017 (lisocabtagene maraleucel) in adults with relapsed or refractory indolent B-cell non-Hod…
-
CLINICAL_TRIALS other · 2025-10-06Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma [Phase 1]
Phase 1 results from a three-drug combination (CC-486/azacitidine, lenalidomide, and obinutuzumab) in patients with recurrent or refractory …
-
CLINICAL_TRIALS research · 2025-04-24Clinical Trial Update: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL [Phase 1, Phase 2]
This clinical trial update describes a Phase 1/2 study evaluating BI-1206 in combination with Rituximab with or without Acalabrutinib in sub…
-
CLINICAL_TRIALS trial_result · 2025-04-11Clinical Trial Update: Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating mosunetuzumab with or without polatuzumab vedotin and obinutuzumab for untreated indolent B-cell non-Hod…
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies [Phase 1]
Phase 1 study evaluating autologous CD19 CAR-T cell therapy SYNCAR-001 with orthogonal IL-2 STK-009 in CD19-positive hematologic malignancie…
-
CLINICAL_TRIALS trial_result · 2024-07-03Clinical Trial Update: QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab [Phase 1, Phase 2]
The QUILT-3.002 trial evaluating N-803 in combination with Rituximab for relapsed/refractory indolent B-cell non-Hodgkin lymphoma has been t…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating Ga-68-CXCR4 PET/CT imaging in patients with indolent B-cell non-Hodgkin lymphoma, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases [Phase 2]
A Phase 2 pembrolizumab trial in untreated B-cell non-Hodgkin lymphoproliferative diseases has been terminated; results have been posted.
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating Rituxan (rituximab) with beta-glucan PGG in relapsed indolent B-cell non-Hodgkin lymphoma has completed, with resul…
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection [Phase 2]
Phase 2 trial evaluating bendamustine hydrochloride injection for indolent B-cell non-Hodgkin's lymphomas has completed.
-
CLINICAL_TRIALS trial_result · 2018-08-09Clinical Trial Update: Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 2]
Phase 2 trial assessing ofatumumab and bendamustine followed by maintenance ofatumumab for rituximab-relapsed indolent B-cell non-Hodgkin's …
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating GP2013, a rituximab biosimilar, in Japanese patients with CD20-positive low-tumor-burden indolent B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma [Phase 1]
This document notes the completion of a Phase 1 drug-drug interaction study of Ofatumumab with Bendamustine in indolent B-cell non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2014-08-21Clinical Trial Update: A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas [Phase 2]
Phase 2 study evaluating induction and maintenance Rituximab (MabThera) in patients with indolent B-cell non-Hodgkin lymphoma; trial complet…
-
CLINICAL_TRIALS trial_result · 2014-08-06Clinical Trial Update: Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma [Phase 1]
Phase 1 trial update describing treatment with genetically engineered lymphocytes, cyclophosphamide, and aldesleukin in relapsed or refracto…
-
CLINICAL_TRIALS trial_result · 2012-08-28Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) [Phase 2]
Phase 2 study evaluating the efficacy and safety of combining bendamustine with ofatumumab as first-line therapy for indolent B-cell non-Hod…